From Wikipedia, the free encyclopedia
Jump to: navigation, search
Repaglinide ball-and-stick.png
Systematic (IUPAC) name
(S)-(+)-2-ethoxy-4-[2-(3-methyl-1-[2-(piperidin-1-yl)phenyl]butylamino)-2-oxoethyl]benzoic acid
Clinical data
Trade names Prandin
AHFS/ monograph
MedlinePlus a600010
Licence data EMA:Link, US FDA:link
  • AU: C
  • US: C (Risk not ruled out)
Legal status
Routes of
Pharmacokinetic data
Bioavailability 56% (oral)
Protein binding >98%
Metabolism Hepatic oxidation and glucuronidation (CYP3A4-mediated)
Biological half-life 1 hour
Excretion Fecal (90%) and renal (8%)
CAS Registry Number 135062-02-1 YesY
ATC code A10BX02
PubChem CID: 65981
DrugBank DB00912 YesY
ChemSpider 59377 YesY
UNII 668Z8C33LU YesY
KEGG D00594 YesY
Chemical data
Formula C27H36N2O4
Molecular mass 452.586 g/mol
 YesY (what is this?)  (verify)

Repaglinide is an antidiabetic drug in the class of medications known as meglitinides, and was invented in 1983. It is sold by Novo Nordisk under the name of Prandin in the U.S., GlucoNorm in Canada, Surepost in Japan, Repaglinide in Egypt by EIPICO, and NovoNorm elsewhere. In Japan it is produced by Dainippon Sumitomo Pharma.


Repaglinide is used for diabetes mellitus type 2.

Adverse events[edit]

Hypoglycemia, diarrhea, nausea, rash and weight gain.

Drug interactions[edit]

Repaglinide is a major substrate of CYP3A4 and should not be administered concomitantly with gemfibrozil, clarithromycin or azole antifungals such as itraconazole or ketoconazole[citation needed]. Administration of both repaglinide and one or more of these drugs results in an increase in plasma concentration of repaglinide and may lead to hypoglycemia. Repaglinide should not be combined with sulfonylurea, because they have the same mechanism of action.


Type 1 diabetes, severe liver disease, pregnancy and lactation are contraindications.

Comparisons with other drugs for type 2 diabetes[edit]

A study funded by Novo Nordisk, the U.S. distributor for Repaglinide, compared their product with Nateglinide in "A randomized, parallel-group, open-label, multicenter 16-week clinical trial".[1] They concluded that the two were similar, but "repaglinide monotherapy was significantly more effective than nateglinide monotherapy in reducing HbA1c and FPG values after 16 weeks of therapy." However, 7 percent of the Repaglinide patients "had minor hypoglycemic episodes (blood glucose <50 mg/dl) versus 0 patients for nateglinide"; this difference was not statistically significant. They also cited a 1-year study that concluded that "repaglinide had similar efficacy to glyburide."

Mechanism of Action[edit]

Repaglinide lowers blood glucose by stimulating the release of insulin from the pancreas. It achieves this by closing ATP-dependent potassium channels in the membrane of the beta cells. This depolarizes the beta cells, opening the cells' calcium channels, and the resulting calcium influx induces insulin secretion.


Precursor drugs to repaglinide were invented in late 1983 by scientists at Dr Karl Thomae GmbH, a German drug manufacturer located at Biberach an der Riß in southern Germany which was acquired by Boehringer Ingelheim in 1990. The drug that became repaglinide was later licensed by Boehringer to Novo Nordisk, which filed an Investigational New Drug application for the compound with the Food and Drug Administration (FDA) in April 1992. Novo Nordisk filed its New Drug Application (NDA) for Prandin in July 1997 and it was quickly approved, gaining FDA approval in December 1997. The drug was the first of the meglitinide class. It was branded Prandin because its quick onset and short duration of action concentrates its effect around meal time (the prandium was the Roman meal which is comparable to the modern lunch).

Intellectual property[edit]

After several attempts to file for U.S. patent protection, a filing was made in March 1990 which eventually became U.S. Patents 5,216,167 (June 1993), 5,312,924 (May 1994) and 6,143,769 (November 2000). After filing its NDA for repaglinide in 1997, Novo Nordisk applied for patent extension under the Hatch-Waxman Act. This process, called patent term restoration, allows drug patents to be extended based on the time that a drug spent in clinical trials and in the approval process. Previously it had been decided by the U.S. Patent and Trademark Office that the expiration date of U.S. Patents 5,216,167 and 5,312,924 would be 5 September 2006. In February 2001 Prandin's patent life was extended to 14 March 2009 in response to Novo Nordisk's patent term restoration application, with U.S. Patent 5,216,167 having been reissued as RE37035.[2]

Prior to the end of repaglinide's patent term, Novo Nordisk obtained a new patent, U.S. Patent 6,677,358 (January 2004), covering the combination therapy of repaglinide together with the generic anti-diabetic drug metformin. This new patent was due to expire June 2018. In January 2011, a federal court ruled Novo Nordisk's new patent invalid on the grounds of obviousness, and unenforceable on the grounds of inequitable conduct on the part of Novo Nordisk's patent attorneys.[3]


Repaglinide is available in 0.5 mg, 1 mg and 2 mg tablets.

See also[edit]


  1. ^ Rosenstock, Julio Rosenstock; Hassman, David R.; Madder, Robert D.; Brazinsky, Shari A.; Farrell, James; Khutoryansky, Naum; Hale, Paula M. (June 2004), "Repaglinide Versus Nateglinide Monotherapy: A randomized, multicenter study", Diabetes Care (American Diabetes Association) 27 (6): 1265–1270, doi:10.2337/diacare.27.6.1265, retrieved 2014-11-20 
  2. ^ "Details for Patent: RE37035". 
  3. ^ Frankel, Alison (2011-01-27). "Judge Finds Novo Nordisk Diabetes Drug Patent Invalid and Unenforceable, Questions In-House Patent Lawyer's Conduct". Retrieved 2011-02-05. 

External links[edit]